These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 33997096)

  • 21. New Treatments in Spinal Muscular Atrophy: Positive Results and New Challenges.
    Messina S; Sframeli M
    J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32668756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combinatorial treatment for spinal muscular atrophy: An Editorial for 'Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells' on page 264.
    Poletti A; Fischbeck KH
    J Neurochem; 2020 Apr; 153(2):146-149. PubMed ID: 32056234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nusinersen: A Novel Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy.
    Neil EE; Bisaccia EK
    J Pediatr Pharmacol Ther; 2019; 24(3):194-203. PubMed ID: 31093018
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risdiplam in Spinal Muscular Atrophy: Safety Profile and Use Through The Early Access to Medicine Scheme for the Paediatric Cohort in Great Britain.
    Cornell N; Childs AM; Wraige E; Munot P; Ambegaonkar G; Chow G; Hughes I; Illingworth M; Majumdar A; Marini-Bettolo C; Parasuraman D; Spinty S; Willis T; Scoto M; Baranello G;
    J Neuromuscul Dis; 2024; 11(2):361-368. PubMed ID: 38189761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bridging the Gap: Gene Therapy in a Patient With Spinal Muscular Atrophy Type 1.
    Costamagna G; Govoni A; Wise A; Corti S
    Neurology; 2022 Nov; 99(21):952-956. PubMed ID: 36319109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cognitive function in SMA patients with 2 or 3 SMN2 copies treated with SMN-modifying or gene addition therapy during the first year of life.
    Steffens P; Weiss D; Perez A; Appel M; Weber P; Weiss C; Stoltenburg C; Ehinger U; von der Hagen M; Schallner J; Claussen B; Lode I; Hahn A; Schuler R; Ruß L; Ziegler A; Denecke J; Johannsen J
    Eur J Paediatr Neurol; 2024 Jul; 51():17-23. PubMed ID: 38772209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG).
    Finkel RS; Darras BT; Mendell JR; Day JW; Kuntz NL; Connolly AM; Zaidman CM; Crawford TO; Butterfield RJ; Shieh PB; Tennekoon G; Brandsema JF; Iannaccone ST; Shoffner J; Kavanagh S; Macek TA; Tauscher-Wisniewski S
    J Neuromuscul Dis; 2023; 10(3):389-404. PubMed ID: 36911944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nusinersen treatment of Spinal Muscular Atrophy Type 1 - results of expanded access programme in Poland.
    Modrzejewska S; Kotulska K; Kopyta I; Grędowska E; Emich-Widera E; Tomaszek K; Paprocka J; Chmielewski D; Pilch J; Pietruszewski J; Lemska A; Zawadzka M; Mazurkiewicz-Bełdzińska M
    Neurol Neurochir Pol; 2021; 55(3):289-294. PubMed ID: 33565602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risdiplam: A Review in Spinal Muscular Atrophy.
    Paik J
    CNS Drugs; 2022 Apr; 36(4):401-410. PubMed ID: 35284988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug treatment for spinal muscular atrophy types II and III.
    Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD006282. PubMed ID: 32006461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison.
    Ribero VA; Daigl M; Martí Y; Gorni K; Evans R; Scott DA; Mahajan A; Abrams KR; Hawkins N
    J Comp Eff Res; 2022 Apr; 11(5):347-370. PubMed ID: 35040693
    [No Abstract]   [Full Text] [Related]  

  • 32. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial.
    Day JW; Finkel RS; Chiriboga CA; Connolly AM; Crawford TO; Darras BT; Iannaccone ST; Kuntz NL; Peña LDM; Shieh PB; Smith EC; Kwon JM; Zaidman CM; Schultz M; Feltner DE; Tauscher-Wisniewski S; Ouyang H; Chand DH; Sproule DM; Macek TA; Mendell JR
    Lancet Neurol; 2021 Apr; 20(4):284-293. PubMed ID: 33743238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The First Orally Deliverable Small Molecule for the Treatment of Spinal Muscular Atrophy.
    Singh RN; Ottesen EW; Singh NN
    Neurosci Insights; 2020; 15():2633105520973985. PubMed ID: 33283185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Onasemnogene abeparvovec for the treatment of spinal muscular atrophy.
    McMillan HJ; Proud CM; Farrar MA; Alexander IE; Muntoni F; Servais L
    Expert Opin Biol Ther; 2022 Sep; 22(9):1075-1090. PubMed ID: 35437095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Combination of modifying therapies in type 2 spinal muscular atrophy].
    Meza-Cano ME; Dávila-Martínez V
    Rev Med Inst Mex Seguro Soc; 2022 Aug; 60(5):577-583. PubMed ID: 36049072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current and emerging therapies for Duchenne muscular dystrophy and spinal muscular atrophy.
    Iftikhar M; Frey J; Shohan MJ; Malek S; Mousa SA
    Pharmacol Ther; 2021 Apr; 220():107719. PubMed ID: 33130193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risdiplam for the Use of Spinal Muscular Atrophy.
    Kakazu J; Walker NL; Babin KC; Trettin KA; Lee C; Sutker PB; Kaye AM; Kaye AD
    Orthop Rev (Pavia); 2021; 13(2):25579. PubMed ID: 34745484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice.
    Torres-Benito L; Schneider S; Rombo R; Ling KK; Grysko V; Upadhyay A; Kononenko NL; Rigo F; Bennett CF; Wirth B
    Am J Hum Genet; 2019 Jul; 105(1):221-230. PubMed ID: 31230718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Antisense Oligonucleotide Nusinersen for Treatment of Spinal Muscular Atrophy.
    Edinoff AN; Nguyen LH; Odisho AS; Maxey BS; Pruitt JW; Girma B; Cornett EM; Kaye AM; Kaye AD
    Orthop Rev (Pavia); 2021; 13(2):24934. PubMed ID: 34745470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spinal muscular atrophy - new therapies, new challenges.
    Jędrzejowska M; Kostera-Pruszczyk A
    Neurol Neurochir Pol; 2020; 54(1):8-13. PubMed ID: 31922583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.